Search
Research
Novel intranasal phage-CaEDTA-ceftazidime/avibactam triple combination therapy demonstrates remarkable efficacy in treating Pseudomonas aeruginosa lung infectionGiven the rise of multidrug-resistant (MDR) Pseudomonas aeruginosa infections, alternative treatments are needed. Anti-pseudomonal phage therapy shows promise, but its clinical application is limited due to the development of resistance and a lack of biofilm penetration.Â
News & Events
New funding to accelerate AI personalised phage therapiesWal-yan researchers have been awarded $500,000 for their innovative research, supported by the Western Australian Government’s Future Health Medical Research and Innovation (FHRI) Fund.
Research
Lytic activity, stability, biofilm disruption capabilities and genomic characterisation of two bacteriophages active against respiratory MRSAThis study aimed to characterise bacteriophages for potential therapeutic use against Staphylococcus aureus, focusing on clinical respiratory isolates of methicillin-sensitive (MSSA) and methicillin-resistant (MRSA) strains. Specifically, it sought to evaluate phage lytic activity, host range, stability, biofilm disruption capabilities, and overall safety for therapeutic use.